Modified dsRNA Conjugates for Targeted Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dsRNAs struggle to effectively activate TLR-3 and RLR, particularly RIG-I, in cells that are not implicated in the immune response, limiting their application in immunostimulation and treatment of diseases.
Innovation Solution
Development of double-stranded ribonucleic acids (dsRNAs) with specific chemical modifications at the 5′ and 3′ ends, including a free 5′-triphosphate group and covalent modifications, which enable targeted uptake and activation of immune cells by conjugating with carrier groups such as antibodies or liposomes, ensuring specific delivery to target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If dsRNA is used to activate TLR-3 and RLR in immune cells, then immunostimulatory effect is achieved, but dsRNA cannot be taken up by non-immune cells which limits therapeutic application
Solution Approach 1:
The patent introduces carrier groups (such as cell-penetrating peptides, antibodies, or lipids) as intermediaries that facilitate dsRNA uptake into non-immune cells. These carriers mediate the delivery of dsRNA across cell membranes, enabling activation of TLR-3 and RLR in previously inaccessible cell types while maintaining the immunostimulatory function of the original dsRNA molecule.
Solution Approach 2:
The patent applies chemical modifications at specific locations (5′ end, 3′ end, or internal positions) of the dsRNA molecule to confer cell-specific uptake properties. By modifying only certain regions of the dsRNA while preserving the immunostimulatory domains, the invention enables differential cell uptake without compromising the overall activation effectiveness across diverse cell types.
2Adaptability or versatility
If chemical modifications are added to dsRNA to enable targeted uptake, then delivery to non-immune cells is improved, but molecular complexity increases
Solution Approach 1:
The patent divides the dsRNA molecule into functional segments: an immunostimulatory core (the dsRNA itself) and separate modular carrier groups or chemical modifications. This segmentation allows the complex functionality to be achieved through组合 of simpler, well-characterized components, making the overall system more manageable and easier to produce despite the increased capability.
Solution Approach 2:
The patent employs universal carrier groups or chemical modification strategies that can be applied to various dsRNA sequences and target different cell types. By using multi-functional carriers that can bind to different cell surface receptors or penetrate different cell membranes, the invention achieves broad targeted delivery capability without requiring entirely different molecular structures for each application, thus controlling complexity.
3Productivity
If dsRNA is modified with carrier groups for cell uptake, then uptake efficiency in non-immune cells increases, but specificity of immune cell activation may be reduced
Solution Approach 1:
The patent carefully adjusts parameters such as the charge, hydrophobicity, and size of carrier groups to optimize uptake efficiency in non-immune cells while maintaining specificity. By controlling these physical-chemical parameters, the invention achieves enhanced delivery to target cells without causing excessive or non-specific activation of immune cells, thus balancing productivity with reduced off-target effects.
Data Source
AI summary
Double-stranded ribonucleic acids (dsRNA) of at least 45 bp, preferably of at least 50 bp, which dsRNA include at least one 5′-triphosphate group and further includes at least one chemical modification at a 5′ end, at a 3′ end and/or at a non-terminal nucleotide. The invention further provides pharmaceutical compositions containing such modified dsRNAs, methods for their production, and to their use in medicine, in particular for immunostimulation and treatment as well as prevention of infectious, autoimmune, degenerative, cancer and tumor diseases.